This Small-Cap Stock Announces Rs 20 Final And Rs 4 Special Dividend: What's Your Trading Strategy?

Part of RPG Enterprises, RPG Life Sciences Ltd. is a holistic pharmaceutical company that works in the worldwide generics, synthetic APIs, and branded formulations markets both nationally and internationally. In addition to a 300% dividend proposal for FY25, RPG Life Sciences Limited released its financial results for the fourth quarter and year ended March 31, 2025. As a consequence, the company's stock finished Tuesday on the BSE 3.26% higher at Rs 2177.45 per share, with a market valuation of Rs 3,601.29 Cr.

RPG Enterprises Dividend

The Board of Directors "Recommended of final dividend of Rs. 20 (Rupees Twenty only) per equity share (250% on the face value of Rs.8 each) and additionally a special dividend of Rs. 4 (Rupees Four only) per equity share (50% on the face value of Rs. 8 each) on account of significant exceptional profit on assignment of land for the financial year 2024-25, subject to the approval of shareholders at the ensuing Annual General Meeting," said RPG Enterprises in a stock exchange filing.

RPG Enterprises Q4 Results

In the quarter that ended in March 2025, RPG Life Sciences' net profit increased by 786.33% to Rs 117.35 crore, compared to Rs 13.24 crore in the quarter that ended in March 2024. Compared to Rs 126.99 crore in Q4FY24, sales increased 12.68% to Rs 143.09 crore in Q4FY25. From Rs 35.54 crore in Q3 FY24 to Rs 46.89 crore in Q3 FY25, profit before tax (PBT) increased by 31.93%.

During the quarter, overall expenses increased by 7.53% YoY to Rs 129.13 crore. In the year ending in March 2025, net profit increased by 109.03% to Rs 183.24 crore, compared to Rs 87.66 crore in the year ending in March 2024. Compared to Rs 582.05 crore in the entire fiscal year FY24, sales increased 12.26% to Rs 653.43 crore in FY25.

"We are quite on course in shaping our International Formulations and API businesses to emerge as second and third growth engines by way of modernisation of both our API and Formulations plants, setting up new R&D units, developing a strong product pipeline, by infusion of significant capex. The International Formulations business is registering healthy double-digit profitable growth, and the API business is also showing promising profitable growth. Our structural approach of cost optimisation has helped us explore newer avenues in our operations to achieve cost efficiencies, thereby helping us to maintain our uninterrupted Y-o-Y margin expansion trajectory," said Mr. Yugal Sikri, Managing Director, RPG Life Sciences.

"The Company has built sizeable cash surplus of ~Rs. 168 crores from operations as a result of continued remarkable business performance. Additional cash generated by assignment of surplus vacant leasehold land at our Navi Mumbai plant has further augmented the pool to ~Rs. 266 crores. We are actively pursuing inorganic opportunities to accelerate business growth. On the back of continued robust performance, The Board of Directors has recommended highest ever dividend of 250% plus a special dividend of 50% on the face value of Rs. 8 each for FY25, subject to the approval of shareholders at the ensuing Annual General Meeting, thus maintaining an upward trajectory of dividend for the last 6 years," he further added.

RPG Enterprises Share Price Target

"RPG Life Sciences is showing weakness on the charts. The stock recently fell below the ₹2200 support level, which is a negative sign. The selling volume is high, and momentum indicators like RSI are also pointing downwards. It may find some support near ₹2100, but if that breaks, it could slip further toward ₹2050. Unless the stock moves back above ₹2240, the trend will likely stay weak. It's better to avoid buying for now, or sell on any small rise," commented Riyank Arora - Technical Analyst - Mehta Equities Limited.

Disclaimer

The recommendations made above are by market analysts and are not advised by either the author, nor Greynium Information Technologies. The author, nor the brokerage firm nor Greynium would be liable for any losses caused as a result of decisions based on this write-up. Goodreturns.in advises users to consult with certified experts before making any investment decision.